Skip to main content

Advertisement

Table 1 Comparison of baseline demographic characteristics, clinical and biomarker measures in radiographic progressor groups at 8.2 years

From: Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up

  Low Progressors* High Progressors* Comparison SRC
Cohort characteristics (n= 29) (n= 29) z P $ rho P
Demographic       
Female, no. (%) 22 (76%) 15 (52%) 3.66 0.100 - NA
Age, mean ± SD, years 52 ± 10 55 ± 12 0.97 0.334 - NA
Disease duration, days 260 (169, 412) 242 (146, 384) -0.59 0.555 - NA
DAS28 5.1 (4.0, 6.1) 6.2 (4.8, 6.8) 1.73 0.083 - NA
HAQ 1.3 (0.9, 2.0) 1.5 (1.0, 2.3) 0.90 0.370 - NA
No. DMARDsφ 2 (1, 2) 2 (2, 3) 1.81 0.070 - NA
MTX, no. (%)φ 8 (28) 21 (72) 11.66 0.001 - NA
Traditional measures       
Total SHS 3 (0, 8) 16 (6, 28) 4.09 < 0.001 0.51 < 0.001
ESR, mm/hour 19 (11, 39) 34 (20, 50) 2.33 0.020 0.35 0.008
CRP mg/L 8 (5, 20) 34 (15, 65) 3.42 < 0.001 0.46 < 0.001
RF positive, no. (%) 19 (66%) 26 (90%) 4.86 0.056 0.47 < 0.001
Anti-CCP +ve, no. (%)φ 14 (48%) 26 (90%) 11.60 0.001 0.23 0.077
SJC 6 (2, 12) 10 (5, 15) 1.80 0.072 0.19 0.145
TJC 14 (5, 18) 15 (7, 18) 0.47 0.640 0.06 0.675
CGA on VAS, mm 24 (10, 57) 54 (38, 68) 2.48 0.013 0.34 0.010
PGA on VAS, mm 39 (27, 48) 47 (24, 65) 0.53 0.600 0.10 0.447
Biomarkers       
MMP-3, ng/mL 51 (32, 86) 137 (86, 359) 3.83 < 0.001 0.46 < 0.001
CTX-II, μg/mmol 0.14 (0.08, 0.25) 0.36 (0.19, 0.57) 3.40 < 0.001 0.40 0.003
COMP, U/L 10 (8, 11) 13 (11, 16) 3.27 0.001 0.39 0.003
TIMP-1, ng/mL 647 (466, 719) 817 (669, 902) 2.34 0.019 0.29 0.029
  1. *Except where indicated otherwise, values are median (25th and 75th percentiles). $Determined by Mann Whitney U test unless indicated otherwise. Determined by Fisher's two-sided exact test. Determined by Student's t test. φ Value taken at 8.2-year follow-up visit.
  2. Anti-CCP, anti-cyclic citrullinated peptide; CGA, clinician's global assessment; COMP, cartilage oligomeric matrix protein; CRP, C-reactive protein; CTX-II, C-telopeptide of type II collagen; DAS, disease activity score; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; NA, not applicable; NS, not significant; PGA, patient's global assessment; RF, rheumatoid factor; SD, standard deviation; SHS, van der Heijde modified Sharp score; SJC, swollen joint count; SRC, Spearman's rank correlation; TIMP-1, tissue inhibitor of metalloproteinase 1; TJC, tender joint count; VAS, visual analogue score.